**Supplementary Table 1** Antibodies In This Study

|  |  |  |
| --- | --- | --- |
| **Antibodies against** | **Company** | **Catalog number** |
| LETM1 | Abnova | H00003954-M03 |
| SOX2 | Millipore | AB5603 |
| LSD1 | Cell Signaling | 2139 |
| LGR5 | Abcam | ab75732 |
| CD44 | Abcam | ab51037 |
| CD68 | NOVUS | NB120-16518 |
| CD105 | Abcam | ab170943 |
| HIF1α | Proteintech | 20960-1-AP |
| cyclinD1 | Abcam | ab134175 |
| cyclinB1 | Abcam | ab32053 |
| p16 | Millipore | MAB4133 |
| p21 | Millipore | 07-415-1 |
| p27 | Millipore | 06-445 |
| CDK4 | Millipore | MAB8879 |
| pPI3K-p85 | Abcam | ab86714 |
| pAkt-Ser473 | Millipore | 05-1003 |
| pAkt-Thr308 | Millipore | 07-1398 |
| NFκB-p65 | CST | #3034 |
| Snail | Abcam | ab53519 |
| E-cadherin | Abcam | ab40772 |
| vimentin | Millipore | [MABT121](http://www.merckmillipore.com/CN/zh/product/Anti-Vimentin-Antibody-clone-3CB2,MM_NF-MABT121) |

**Supplementary Table 2** The Sequence Of LETM1 esiRNA

|  |  |
| --- | --- |
| **Gene** | **Sequence** |
| LETM1 | GTTCGCGATGACTCGGTAGTAGAGAAGTCCCTCAAGTCCTTGAAGGACAAGAACAAGAAGCTGGAGGAAGGCGGCCCGGTGTACAGCCCCCCCGCAGAGGTGGTGGTGAAGAAGTCCCTGGGGCAGCGGGTGCTGGACGAGCTGAAGCACTACTACCATGGCTTCCGCCTGCTATGGATCGACACCAAGATCGCGGCACGCATGCTCTGGCGCATCCTCAACGGCCACAGCCTGACCCGCCGGGAGCGCAGGCAGTTTCTCCGGATCTGCGCTGACCTCTTCCGCCTGGTGCCGTTCCTTGTGTTCGTGGTGGTGCCGTTCATGGAGTTTCTGCTGCCTGTTGCTGTGAAGCTCTTCCCCAACATGTTGCCATCCACATTTGAGACTCAGTCACTCAAGGAGGAGAGGCTGAAGAAGGAGCTTCGGGTCAAGCTGGAGCTGGCCAAGTTCCTCCAGGACACCATCGAGGAGAT |

Supplementary Table 3 LETM1 Protein Expression In Prostate Lesions

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Diagnosis** | **n** | **LETM1(-)**  **n(%)** | **LETM1(+)**  **n(%)** | **χ2** | **R** | **P** |
|  |  |  |  | 14.250 | 0.311 | <0.001 |
| BPH | 14 | 11(78.6) | 3(21.4) |  |  |  |
| CA | 133 | 38(28.6) | 95(71.4) |  |  |  |

Supplementary Table 4 Univariate And Multivariate Analyses Of Prognostic Variables For Overall Survival In Prostate Cancer Patients Using Cox Proportional Hazards Regression

| **Characteristic** | **Univariate analyses** | | | **Multivariate analyses** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **HR** | **95% CI** | **p-value** | **HR** | **95% CI** | **p-value** |
| Age (years) |  |  | 0.371 |  |  | 0.085 |
| ≦65 | 1.00 |  |  | 1.00 |  |  |
| >65 | 1.350 | 0.700-2.603 |  | 1.812 | 0.922-3.564 |  |
| pT stage |  |  | 0.122 |  |  | 0.972 |
| 1 | 1.00 |  |  | 1.00 |  |  |
| 2-4 | 25.287 | 0.419-15.250 |  | 3.474 | 1.734-5.367 |  |
| Lymph node metastasis |  |  | <0.001 |  |  | <0.001 |
| Negative | 1.00 |  |  | 1.00 |  |  |
| Positive | 3.782 | 1.892-7.560 |  | 3.727 | 1.796-7.735 |  |
| LETM1 |  |  | <0.001 |  |  | 0.006 |
| Negative | 1.00 |  |  | 1.00 |  |  |
| Positive | 0.306 | 0.159-0.591 |  | 0.395 | 0.203-0.766 |  |